| Not Yet Recruiting | Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases NCT07454668 | Baptist Health South Florida | Phase 1 |
| Not Yet Recruiting | Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial) NCT07248228 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Canc NCT07464470 | Blokhin's Russian Cancer Research Center | — |
| Not Yet Recruiting | Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 NCT07462507 | Washington University School of Medicine | Phase 2 |
| Recruiting | Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases NCT07481786 | Sun Yat-sen University | Phase 3 |
| Not Yet Recruiting | Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: NCT07199413 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) NCT07227610 | Medical University of South Carolina | Phase 2 |
| Active Not Recruiting | Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer NCT07448493 | Blokhin's Russian Cancer Research Center | — |
| Recruiting | Feasibility of a Cognitive Stepped Care Program for Adults With Brain Metastases NCT07355348 | University Health Network, Toronto | N/A |
| Recruiting | Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases NCT07053033 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety St NCT07365410 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | MeDex: No Perioperative Dexamethasone in Brain Metastases NCT07044557 | University of Louisville | N/A |
| Enrolling By Invitation | Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Statu NCT07373951 | Ming Yang | — |
| Recruiting | 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCL NCT07175077 | University of Missouri-Columbia | — |
| Recruiting | Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) NCT07139990 | University of Texas Southwestern Medical Center | Phase 1 |
| Not Yet Recruiting | Evolution of Hypofractionated Stereotactic Irradiation for Radio-Resistant Brain Metastases From D1-3-5 to D1- NCT07167134 | Centre Paul Strauss | Phase 3 |
| Recruiting | A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brai NCT06822543 | Latin American Cooperative Oncology Group | Phase 2 |
| Not Yet Recruiting | A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases NCT07177950 | Peking University Cancer Hospital & Institute | Phase 1 / Phase 2 |
| Not Yet Recruiting | Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy NCT07185958 | Aalborg University Hospital | — |
| Recruiting | Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases NCT06620380 | University of Zurich | Phase 2 |
| Recruiting | Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positiv NCT07100600 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Me NCT06712927 | Stanford University | Phase 2 |
| Recruiting | REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis NCT06315010 | MedSIR | Phase 2 |
| Recruiting | Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis NCT06933199 | University Hospital Ostrava | N/A |
| Recruiting | Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases NCT06471465 | Institut Cancerologie de l'Ouest | Phase 3 |
| Recruiting | Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases NCT06857006 | University of Alabama at Birmingham | N/A |
| Recruiting | EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase NCT06649058 | M.D. Anderson Cancer Center | Phase 2 |
| Enrolling By Invitation | Automated Detection of Brain Metastases on MRI NCT06727032 | Robovision BV | — |
| Recruiting | ioMRI in the Surgery of Brain Metastases. NCT07197632 | Technical University of Munich | N/A |
| Recruiting | BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC NCT06793332 | Fudan University | Phase 2 |
| Recruiting | A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pse NCT06015295 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases NCT06702826 | Rongrong Zhou | Phase 2 |
| Recruiting | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas NCT06640582 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Development of MRF for Characterization of Brain Tumors After Radiotherapy NCT06101069 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Efficacy of the Association of Fractionated SRS and Subsequent Surgery in Patients With Brain Metastases NCT06992973 | Regina Elena Cancer Institute | N/A |
| Recruiting | Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis NCT06055790 | University of Arizona | Phase 2 |
| Recruiting | Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for E NCT06728865 | Li-kun Chen | Phase 2 |
| Completed | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent NCT06322342 | Reveal Pharmaceuticals Inc. | Phase 2 |
| Not Yet Recruiting | Evaluation of Brain Metastases Treated With Stereotactic Radiotherapy Using Dynamic [18F]FDG PET NCT06511323 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N/A |
| Active Not Recruiting | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases NCT06282874 | Guangdong Association of Clinical Trials | Phase 4 |
| Recruiting | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Met NCT06501391 | Fudan University | Phase 2 |
| Recruiting | SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer NCT06476093 | The First People's Hospital of Lianyungang | N/A |
| Recruiting | Measuring and Mapping Cognitive Decline After Brain Radiosurgery NCT06466720 | University of Nottingham | — |
| Recruiting | 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery NCT06048094 | Baptist Health South Florida | Phase 1 |
| Recruiting | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases NCT06194929 | University of Utah | Phase 1 / Phase 2 |
| Recruiting | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally S NCT05987644 | Joshua Palmer | Phase 1 / Phase 2 |
| Active Not Recruiting | Multicenter Retrospective Study on Patients Treated with Stereotactic Radiosurgery/Radiotherapy for Single Bra NCT06869460 | Gemelli Molise Hospital | — |
| Recruiting | Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Or NCT05977803 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases NCT05871307 | University Hospital Heidelberg | Phase 2 |
| Terminated | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer NCT05553522 | Baptist Health South Florida | Phase 1 |
| Recruiting | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metasta NCT06243003 | Fudan University | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors NCT06209567 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Recruiting | SGM-101 in Colorectal Brain Metastases. NCT04755920 | Leiden University Medical Center | Phase 2 |
| Recruiting | Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer NCT06072807 | Weill Medical College of Cornell University | Phase 4 |
| Recruiting | Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis NCT05868928 | Asan Medical Center | — |
| Unknown | ANG1005 in Leptomeningeal Disease From Breast Cancer NCT03613181 | Angiochem Inc | Phase 3 |
| Unknown | Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung C NCT05812534 | Second Affiliated Hospital of Nanchang University | Phase 2 |
| Recruiting | Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases NCT05789589 | Baptist Health South Florida | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spr NCT06132945 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | CALM: Managing Distress in Malignant Brain Cancer NCT06180460 | Virginia Commonwealth University | N/A |
| Not Yet Recruiting | A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases NCT06088056 | Fudan University | Phase 2 |
| Enrolling By Invitation | Cryoablation of Brain Neoplasm NCT06753617 | Erasmus Medical Center | N/A |
| Recruiting | Frameless Stereotactic Radiosurgery for Intact Brain Metastases NCT02747303 | University of Chicago | Phase 2 |
| Recruiting | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC NCT06457906 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 |
| Recruiting | Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance NCT05692635 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal M NCT06410040 | Sichuan Cancer Hospital and Research Institute | — |
| Recruiting | TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813 | TYK Medicines, Inc | Phase 2 |
| Active Not Recruiting | SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI NCT06020066 | Fudan University | Phase 2 |
| Withdrawn | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metasta NCT05255666 | Washington University School of Medicine | Phase 2 |
| Completed | Evaluation of the Humoral and Tumoral Molecular Alteration Profile of Brain Metastases NCT05848050 | GCS Ramsay Santé pour l'Enseignement et la Recherche | N/A |
| Recruiting | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancer NCT05700721 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy NCT05996432 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Recruiting | A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic NCT05673928 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients W NCT05807893 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Active Not Recruiting | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-D NCT05323955 | Carey Anders, M.D. | Phase 2 |
| Recruiting | Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brai NCT05768490 | Sun Yat-sen University | Phase 3 |
| Withdrawn | SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell L NCT04650490 | Duke University | Phase 2 |
| Recruiting | Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. NCT06238882 | Instituto Nacional de Cancerologia de Mexico | N/A |
| Unknown | Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Met NCT05737589 | Xiaorong Dong | — |
| Recruiting | ASL in Brain Metastasis MRI Following Gamma Knife Treatment NCT04833335 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis NCT05554302 | Baptist Health South Florida | Phase 2 |
| Recruiting | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases NCT05535413 | Hunan Cancer Hospital | Phase 1 / Phase 2 |
| Recruiting | Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI NCT05464992 | Centre Paul Strauss | N/A |
| Unknown | Treatments for Brain Metastases With Poor Prognostic Factors NCT05609162 | Sun Yat-sen University | — |
| Unknown | Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation NCT05616377 | Sun Yat-sen University | — |
| Recruiting | Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment NCT05559853 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma NCT05048212 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images NCT05573815 | Heuron Inc. | N/A |
| Recruiting | Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer NCT05452005 | University of California, Davis | Phase 1 |
| Active Not Recruiting | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis NCT04074096 | UNICANCER | Phase 2 |
| Active Not Recruiting | Study Assessing QBS72S For Treating Brain Metastases NCT05305365 | Stanford University | Phase 2 |
| Recruiting | Improving Therapeutic Ratio With Hypo Fractionated Stereotactic Radiotherapy for Brain Metastases NCT05346367 | Haaglanden Medical Centre | N/A |
| Completed | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) NCT05465343 | Peking Union Medical College | Phase 2 |
| Recruiting | Evaluation of the CONVIVO System NCT05139277 | Dartmouth-Hitchcock Medical Center | N/A |
| Recruiting | A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain NCT05419076 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cance NCT04512261 | Reva Basho | Phase 1 / Phase 2 |
| Recruiting | REMASTer: REcurrent Brain Metastases After SRS Trial NCT05124912 | Monteris Medical | N/A |
| Recruiting | Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radio NCT04689048 | Baptist Health South Florida | Phase 1 |
| Completed | Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation NCT05146219 | TYK Medicines, Inc | Phase 2 |
| Unknown | Hippocampal-Sparing Stereotactic Radiosurgery Treatment of Brain Metastases Using CyberKnife NCT05177185 | Ottawa Hospital Research Institute | Phase 2 |
| Completed | HyperArc Registry Study NCT05270707 | Varian, a Siemens Healthineers Company | — |
| Active Not Recruiting | Preop fSRS for Resectable Brain Metastases NCT05267587 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873 | Blueprint Medicines Corporation | Phase 1 |
| Recruiting | The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With M NCT05378633 | University Hospital Heidelberg | N/A |
| Terminated | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma NCT04955743 | Yale University | Phase 2 |
| Recruiting | NTS-WBRT in Brain Metastases NCT05013892 | Massachusetts General Hospital | Phase 2 |
| Completed | Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis NCT05762172 | Centre Hospitalier Universitaire, Amiens | N/A |
| Recruiting | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor T NCT05064280 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Preclinical Brain Tumor Models NCT06045065 | Assistance Publique Hopitaux De Marseille | — |
| Unknown | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Canc NCT05588206 | First People's Hospital of Hangzhou | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific NCT05459441 | Shanghai Pudong Hospital | EARLY_Phase 1 |
| Unknown | Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomati NCT05638425 | Xiangya Hospital of Central South University | — |
| Completed | Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases NCT04890028 | Institut Cancerologie de l'Ouest | N/A |
| Recruiting | Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases NCT04923542 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Withdrawn | Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metasta NCT04856475 | Jules Bordet Institute | Phase 2 |
| Recruiting | Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PR NCT05045950 | Medical College of Wisconsin | Phase 2 |
| Unknown | TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) NCT04760431 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Terminated | Pre- Versus Post-operative SRS for Resectable Brain Metastases NCT04474925 | AHS Cancer Control Alberta | Phase 3 |
| Unknown | Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions NCT05358340 | University Health Network, Toronto | N/A |
| Active Not Recruiting | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases NCT04899908 | Brigham and Women's Hospital | Phase 2 |
| Unknown | BRIANSTORM - Early Identification of Patients With Brain Metastases NCT05185557 | Aarhus University Hospital | — |
| Active Not Recruiting | MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases NCT04246879 | Duke University | N/A |
| Unknown | Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases NCT05207904 | Sun Yat-sen University | Phase 2 |
| Recruiting | Intraoperative Radiotherapy in Patients With Brain Metastases NCT04847284 | Parc de Salut Mar | N/A |
| Unknown | the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With B NCT04978753 | Li-kun Chen | Phase 2 |
| Terminated | Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases NCT03698162 | University of Southern California | N/A |
| Active Not Recruiting | Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study) NCT04365374 | GT Medical Technologies, Inc. | Phase 3 |
| Unknown | Use of Non-invasive Optical Analysis in Neurosurgery NCT04712214 | Imperial College London | N/A |
| Unknown | A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTIST NCT04778800 | Henan Cancer Hospital | N/A |
| Recruiting | A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continua NCT05033691 | Hadassah Medical Organization | N/A |
| Unknown | A Study to Assess the Efficacy of Cerebellar IMRT Combined With Cerebral SRS in Patients With Brain Metastases NCT05477316 | Hadassah Medical Organization | N/A |
| Completed | Preoperative Stereotactic Radiosurgery for Brain Metastases NCT04503772 | Centre Jean Perrin | Phase 2 |
| Unknown | Hypofractionated Versus Single Fraction Stereotactic Adjuvant Radiotherapy to the Resection Cavity of Brain Me NCT05160818 | Technical University of Munich | N/A |
| Completed | Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases NCT04545814 | Medical College of Wisconsin | N/A |
| Terminated | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, NCT04610684 | Jeffrey Clarke | Phase 2 |
| Active Not Recruiting | Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC NCT06557187 | Yatian Liu | N/A |
| Unknown | Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (C NCT04700748 | Lund University Hospital | N/A |
| Unknown | Central Nervous System(CNS) Efficacy of Dacomitinib NCT04675008 | Samsung Medical Center | Phase 2 |
| Unknown | Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Posi NCT04334330 | Sun Yat-sen University | Phase 2 |
| Unknown | A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant N NCT04643847 | First People's Hospital of Hangzhou | Phase 2 |
| Terminated | Brigatinib Before Brain Irradiation Trial (B3i Trial) NCT04634110 | University of Colorado, Denver | Phase 2 |
| Completed | Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases NCT04410133 | Blue Earth Diagnostics | Phase 3 |
| Completed | Keynatinib in Treated Patients With NSCLC and Brain Metastases NCT04824079 | Medolution Ltd. | Phase 2 |
| Recruiting | Radiosurgery With or Without Whole Brain Radiation for Multiple Metastases NCT03775330 | Sunnybrook Health Sciences Centre | — |
| Active Not Recruiting | FLT-PET / MRI Brain Mets NCT04244019 | University Health Network, Toronto | — |
| Completed | Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC NCT04507217 | Sun Yat-sen University | Phase 2 |
| Completed | Perfexion Registration Using CBCT NCT04170777 | University Health Network, Toronto | — |
| Completed | Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metasta NCT04410367 | Blue Earth Diagnostics | Phase 2 |
| Terminated | Preoperative SRS/SRT vs Postoperative SRS/SRT for Brain Metastases NCT04422639 | University of Arkansas | N/A |
| Unknown | Phase 1 Trial for Tumor Treating Field for Drug/Radiation Resistant Brain Metastases NCT04967027 | Xiangya Hospital of Central South University | EARLY_Phase 1 |
| Completed | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S NCT04430842 | Quadriga Biosciences, Inc. | Phase 1 |
| Completed | Dosimetric Validation of Scans Generated by GAN From Pre-therapeutic MRI in Stereotactic Cerebral Radiotherapy NCT04525053 | University Hospital, Brest | — |
| Completed | Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation NCT04233021 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Unknown | Dose-staged Gamma Knife Radiosurgery Versus Microsurgical Resection NCT04857905 | Medical University of Vienna | N/A |
| Withdrawn | Single vs Multi-fraction SRS Patients on Immunotherapy NCT04427228 | University of Chicago | Phase 2 |
| Completed | Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT NCT04452084 | National Cancer Centre, Singapore | Phase 2 |
| Recruiting | Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC) NCT04654975 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease NCT04420598 | MedSIR | Phase 2 |
| Terminated | GM1 Prophylaxis for WBRT Related Cognitive Dysfunction NCT04395339 | Sun Yat-sen University | Phase 3 |
| Unknown | A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 A NCT04158947 | xuexin he | Phase 2 |
| Completed | WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors NCT04334863 | Emory University | Phase 1 |
| Unknown | Evaluation of the Best Treatment in Terms of Quality of Life for Patients Having a Brain Metastasis NCT04358666 | University Hospital, Caen | N/A |
| Unknown | HA-WBRT vs SRS in Patients With Multiple Brain Metastases NCT04277403 | Medical University Innsbruck | Phase 3 |
| Withdrawn | Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR NCT05054400 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Terminated | Evaluating AGuIX® Nanoparticles in Combination With Stereotactic Radiation for Brain Metastases NCT04094077 | Centre Leon Berard | Phase 2 |
| Unknown | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC NCT04211090 | Sun Yat-sen University | Phase 2 |
| Unknown | Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases NCT06405256 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Unknown | Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases NCT04582968 | Fudan University | Phase 1 / Phase 2 |
| Unknown | Camrelizumab Combined With Local Treatment in NSCLC Patients With BM NCT04291092 | Zhejiang Cancer Hospital | Phase 2 |
| Terminated | Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study NCT04047602 | Indiana University | N/A |
| Completed | Closed vs. Open Face Masks for Cranial Radiotherapy NCT04079595 | University of Zurich | N/A |
| Active Not Recruiting | GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal NCT04192981 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets NCT04073966 | UNC Lineberger Comprehensive Cancer Center | — |
| Unknown | The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy f NCT04193007 | Second Affiliated Hospital of Nanchang University | Phase 2 |
| Completed | Glucocorticoids, Immunotherapy and Radiosurgery for Brain Metastases NCT04042220 | Medical University of Vienna | — |
| Unknown | SRS Sequential Sindilimab in Brain Metastasis of NSLSC NCT04180501 | Xiaorong Dong | Phase 2 |
| Terminated | Study of Intraoperative Radiotherapy for Patients With Large Brain Metastases Treated With Neurosurgical Resec NCT04040400 | University of Louisville | N/A |
| Recruiting | Stereotactic Magnetic Resonance Guided Radiation Therapy NCT04115254 | Dana-Farber Cancer Institute | N/A |
| Unknown | Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases NCT04001725 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Unknown | Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study NCT03951142 | Kyrre Eeg Emblem | Phase 2 |
| Completed | Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metas NCT03714243 | InSightec | N/A |
| Terminated | Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain NCT03488472 | Drexell Hunter Boggs | N/A |
| Completed | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Bra NCT03898908 | Grupo Español Multidisciplinar de Melanoma | Phase 2 |
| Unknown | FSRT in Breast Cancer Patients With Brain Metastases NCT04061408 | Fudan University | Phase 2 |
| Suspended | Supportive Care With or Without Repeated Whole Brain Radiotherapy in Patients With Recurrent Brain Metastases NCT04084431 | University Hospital Heidelberg | N/A |
| Terminated | Neurosurgical Transitional Care Programme NCT03593330 | Barts & The London NHS Trust | N/A |
| Terminated | An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a Hig NCT03911869 | Pfizer | Phase 2 |
| Unknown | Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer NCT04213170 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases NCT03753685 | Fudan University | Phase 2 |
| Unknown | X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases NCT04415320 | Betta Pharmaceuticals Co., Ltd. | Phase 2 |
| Active Not Recruiting | Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC NCT03769103 | British Columbia Cancer Agency | Phase 2 |
| Completed | Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases NCT03807765 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | DM-CHOC-PEN for Brain Tumors in AYA Subjects NCT03668847 | DEKK-TEC, Inc. | Phase 2 |
| Unknown | A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast C NCT03933982 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | HFSRT With Concurrent TMZ for Large BMs NCT03778541 | Chinese Academy of Medical Sciences | Phase 3 |
| Unknown | Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation NCT03754530 | Betta Pharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine NCT03550391 | Canadian Cancer Trials Group | Phase 3 |
| Recruiting | Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients NCT03449238 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Active Not Recruiting | MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or NCT03881605 | Sunnybrook Health Sciences Centre | N/A |
| Unknown | Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer NCT03638765 | Northwest Biotherapeutics | Phase 1 |
| Completed | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metas NCT03653546 | Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2 / Phase 3 |
| Active Not Recruiting | CBF and NCF Changes With Brain Radiation NCT03606421 | University Health Network, Toronto | — |
| Unknown | The Impact of Neurocognitive Function in Patients With Multiple Brain Metastases Receiving Whole Brain Radiati NCT03626818 | Guangdong Association of Clinical Trials | — |
| Completed | A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases NCT03412812 | University of Alabama at Birmingham | N/A |
| Unknown | A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combine NCT04058704 | Betta Pharmaceuticals Co., Ltd. | Phase 3 |
| Terminated | E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) NCT03332589 | Spirita Oncology, LLC | Phase 1 |
| Terminated | Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases NCT03430947 | Technische Universität Dresden | Phase 2 |
| Terminated | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma NCT03728465 | University Hospital Tuebingen | Phase 2 |
| Active Not Recruiting | LIFE - Lung Cancer, Immunotherapy, Frailty, Effect NCT03870464 | University of Southern Denmark | — |
| Completed | Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases NCT03398694 | Indiana University | N/A |
| Completed | A Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases NCT03368625 | University Health Network, Toronto | N/A |
| Active Not Recruiting | Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases NCT03391362 | Dana-Farber Cancer Institute | N/A |
| Terminated | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and NCT02974803 | Canadian Cancer Trials Group | Phase 2 |
| Completed | Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence NCT03303365 | Juergen Debus | N/A |
| Withdrawn | Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma NCT03297463 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Unknown | Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery NCT03520829 | Assistance Publique Hopitaux De Marseille | — |
| Unknown | Brain Metastases in Norway - A Prospective Cohort Study NCT03346655 | Oslo University Hospital | — |
| Recruiting | Phase I Study of Fractionated Stereotactic Radiation Therapy NCT03726359 | Albert Einstein College of Medicine | Phase 1 |
| Unknown | Hippocampus-sparing WBRT and Simultaneous Integrated Boost for Multiple Brain Metastases From NSCLC NCT03366376 | Samsung Medical Center | Phase 2 |
| Recruiting | Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS NCT03324360 | Sunnybrook Health Sciences Centre | Phase 1 |
| Active Not Recruiting | Neurocognitive Decline in Patients With Brain Metastases NCT03508752 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Completed | Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases NCT03297788 | Juergen Debus | N/A |
| Unknown | Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer NCT03356600 | Shanxi Province Cancer Hospital | Phase 2 |
| Unknown | Short Course Radiation Therapy in Palliative Treatment of Brain Metastases NCT03525301 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A |
| Terminated | Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain M NCT03189381 | Indiana University | N/A |
| Terminated | Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metast NCT02460874 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Recruiting | Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases NCT03223922 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Active Not Recruiting | Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors NCT03163368 | Cedars-Sinai Medical Center | EARLY_Phase 1 |
| Unknown | A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Canc NCT03257735 | Sun Yat-sen University | — |
| Active Not Recruiting | Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases NCT03075072 | Dana-Farber Cancer Institute | N/A |
| Unknown | Intraoperative Radiotherapy After the Resection of Brain Metastases NCT03226483 | Universitätsmedizin Mannheim | N/A |
| Unknown | Memory Preservation of Hippocampal Avoidance Whole Brain Radiotherapy NCT03247127 | Kaohsiung Medical University Chung-Ho Memorial Hospital | N/A |
| Completed | Re-craniotomy and Complications After Elective Neurosurgery NCT03910556 | Chiang Mai University | — |
| Unknown | Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases NCT03414944 | Shandong Cancer Hospital and Institute | N/A |
| Unknown | Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGF NCT02972333 | Shandong Cancer Hospital and Institute | Phase 3 |
| Active Not Recruiting | Pembrolizumab In Central Nervous System Metastases NCT02886585 | Massachusetts General Hospital | Phase 2 |
| Completed | Hippocampal Sparing Whole Brain Radiotherapy vs Conventional Whole Brain Radiotherapy in Patients With Brain M NCT02147028 | University College, London | Phase 2 |
| Completed | nTMS for Motor Mapping of Rolandic Lesions NCT02879682 | Technical University of Munich | Phase 2 / Phase 3 |
| Terminated | Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Br NCT02490878 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Withdrawn | 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets NCT02735798 | Pamela Munster | EARLY_Phase 1 |
| Unknown | Neurocognitive Impact and Dose-Effect Relationship of Hippocampal Avoidance During Whole Brain Radiotherapy Pl NCT03223675 | Chang Gung Memorial Hospital | N/A |
| Unknown | High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases NCT02726568 | Betta Pharmaceuticals Co., Ltd. | Phase 2 |
| Completed | Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles NCT02820454 | University Hospital, Grenoble | Phase 1 |
| Completed | Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis NCT02605746 | St. Joseph's Hospital and Medical Center, Phoenix | EARLY_Phase 1 |
| Completed | Clinical Evaluation of the Treatment of Intellectual Metastases by Radiosurgery Gamma Knife by Means of a Supp NCT02732769 | Assistance Publique Hopitaux De Marseille | N/A |
| Completed | HA-WBRT-SIB for Brain Metastasis of Lung Cancer NCT06289023 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Completed | FSRT Combined With TMZ for Large BMs: a PSM Study NCT03338075 | Chinese Academy of Medical Sciences | — |
| Unknown | Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer NCT01951469 | Sun Yat-sen University | Phase 3 |
| Completed | Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-S NCT01951482 | Sun Yat-sen University | Phase 3 |
| Withdrawn | Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cel NCT02014545 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate NCT02581839 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases NCT02616393 | Kadmon Corporation, LLC | Phase 2 |
| Completed | Comparing Immobilisation Shells in Cranial Radiotherapy NCT02599142 | Royal Marsden NHS Foundation Trust | N/A |
| Unknown | Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer NCT03002532 | Affiliated Hospital to Academy of Military Medical Sciences | N/A |
| Completed | Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor NCT02576522 | Istituto Clinico Humanitas | N/A |
| Recruiting | Stereotactic Radiosurgery Dose Escalation for Brain Metastases NCT02390518 | University of Utah | Phase 1 |
| Completed | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma NCT02308020 | Eli Lilly and Company | Phase 2 |
| Completed | Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases NCT02215512 | EpicentRx, Inc. | Phase 1 |
| Active Not Recruiting | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases NCT02374242 | Melanoma Institute Australia | Phase 2 |
| Unknown | Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth F NCT02338011 | Shanghai Chest Hospital | Phase 2 / Phase 3 |
| Unknown | High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases NCT02284490 | Rongjie Tao | Phase 2 |
| Terminated | Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases NCT02187822 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Whole Brain Radiotherapy Versus Volumetric Modulated Arc Therapy for Brain Metastases NCT02220491 | British Columbia Cancer Agency | N/A |
| Unknown | Tomotherapy for Refractory Brain Metastases NCT03027544 | Chinese Academy of Medical Sciences | N/A |
| Completed | Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases NCT04178330 | Chinese Academy of Medical Sciences | N/A |
| Completed | Toronto BNB Pilot Study NCT02082587 | University Health Network, Toronto | — |
| Completed | CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases NCT02058953 | University of Pittsburgh | — |
| Withdrawn | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases NCT02065466 | University of Arizona | Phase 1 / Phase 2 |
| Completed | STAR Cape+BKM120 MBC With Brain Met NCT02000882 | US Oncology Research | Phase 2 |
| Withdrawn | FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions NCT02328300 | UNC Lineberger Comprehensive Cancer Center | — |
| Unknown | Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastas NCT02185352 | National Taiwan University Hospital | Phase 2 |
| Completed | GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases NCT02115139 | Grupo Español Multidisciplinar de Melanoma | Phase 2 |
| Terminated | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery NCT02097732 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Simvastatin Effect on Radiation Therapy of Brain Metastases NCT02104193 | Ain Shams University | Phase 2 |
| Completed | ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases NCT02048059 | Angiochem Inc | Phase 2 |
| Completed | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases NCT02085070 | Yale University | Phase 2 |
| Completed | 18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases NCT02037945 | Memorial Sloan Kettering Cancer Center | N/A |
| Terminated | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Sel NCT02005614 | Yale University | N/A |
| Completed | A Proof-of-principle Study of HBO-SRS for Brain Metastases NCT01850563 | Dartmouth-Hitchcock Medical Center | N/A |
| Completed | Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enh NCT02311556 | Washington University School of Medicine | Phase 1 |
| Withdrawn | Stereotactic Radiosurgery (SRS) for Multiple CNS Mets NCT02567643 | The Cooper Health System | N/A |
| Unknown | Improved Therapy Response Assessment in Metastatic Brain Tumors NCT03458455 | Oslo University Hospital | — |
| Recruiting | A Prospective Study of the Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Neurocognitive F NCT02504788 | Chang Gung Memorial Hospital | N/A |
| Terminated | Hair-sparing Whole Brain Radiotherapy NCT01421316 | University Hospital, Ghent | Phase 2 |
| Terminated | A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radi NCT01821443 | University of California, San Francisco | N/A |
| Withdrawn | Neurocognitive Outcomes In Patients Treated With Radiotherapy For Five Or More Brain Metastases NCT01731704 | University of California, San Francisco | N/A |
| Unknown | A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis NCT02460068 | Italian Network for Tumor Biotherapy Foundation | Phase 3 |
| Completed | Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) NCT01724606 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib NCT01763385 | Wu Jieping Medical Foundation | Phase 2 |
| Terminated | A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases NCT01551680 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 1 |
| Unknown | Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer NCT01688713 | Zhejiang Cancer Hospital | Phase 2 |
| Completed | PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analog NCT01540513 | University of Wisconsin, Madison | N/A |
| Unknown | Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy Afte NCT01535209 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 3 |
| Completed | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases NCT01578668 | Guangzhou Medical University | Phase 2 |
| Completed | Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation NCT01516983 | Betta Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Completed | PET/CT Imaging of Malignant Brain Tumors With 124I-NM404 NCT01516905 | University of Wisconsin, Madison | — |
| Completed | Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases NCT02654106 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases NCT01480583 | Angiochem Inc | Phase 2 |
| Completed | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastase NCT01386580 | BBB-Therapeutics B.V. | Phase 1 / Phase 2 |